Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.73 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.73 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.64 |
| ▸ | TNF | P01375 | 1/20 | 0.64 |
| ▸ | IL1B | P01584 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19953931 | 0.85 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL29922428 | 0.85 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL16209843 | 0.85 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL20845694 | 0.84 | DDB1 (0.64) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL20845674 | 0.84 | DDB1 (0.61) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL30241720 | 0.81 | DDB1 (0.83) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL283184 | 0.80 | CRBN (0.79) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL283314 | 0.80 | CRBN (0.79) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL18900376 | 0.80 | CRBN (0.76) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL282492 | 0.80 | CRBN (0.79) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230038512-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2022255888-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| US-11358948-B2 | CRBN ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200377469-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2020-12-03 | — | — | US | disclosed |
| WO-2019060693-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377469-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | DDB1 304/4885CRBN 1/4885IKZF3 183/4885 |
| US-11358948-B2 | CRBN ligands and uses thereof | CRBN, CRKL, ERBB3 | DDB1 304/4885CRBN 1/4885IKZF3 183/4885 |
| US-20230038512-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | DDB1 304/4885CRBN 1/4885IKZF3 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.